📰 Arnaud Delepine News
Page 2 - Arnaud Delepine News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Arnaud Delepine. Real-time updates on events, politics, business and more.
September 26, 2023
If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat ...
May 21, 2023
Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the... | May 21, 2023
May 21, 2023
FinancialContent fully hosted finance channel
February 18, 2022
TARRYTOWN, N.Y. and PARIS, Feb. 18, 2022 /PRNewswire/ -- In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistic...
February 10, 2022
TARRYTOWN, N.Y. and PARIS, Feb. 10, 2022 /PRNewswire/ --If approved, Dupixent will be the first biologic medicine available in the U.S. to treat u...
January 19, 2022
Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and only medicine to demonstrate positive Phase
January 19, 2022
/PRNewswire/ -- Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of...
January 19, 2022
/PRNewswire/ -- Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of...
January 19, 2022
Investegate announcements from Sanofi - Aventis Groupe, Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
January 7, 2022
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines Collaborative efforts aim to accelerate drug discovery and improve clinical